文献速递临床试验与 GCP

FortiColos——使用牛初乳作为极早产儿母乳强化剂的多中心研究:随机对照先导试验的研究方案

FortiColos - a multicentre study using bovine colostrum as a fortifier to human milk in very preterm infants: study protocol for a randomised controlled pilot trial.
PubMed 文献 · Trials · 2019-05-22

本研究为开放标签多中心随机对照先导试验,计划纳入200名胎龄26+0至30+6周的极早产儿,随机分配至牛初乳强化剂组或牛乳强化剂组,添加至母乳和/或捐赠人乳中。主要结局包括生长速率、坏死性小肠结肠炎和晚发型脓毒症发生率、一系列副临床终点及新型强化剂的实际可行性。该试验将记录牛初乳作为极早产儿母乳新型强化剂的可行性、安全性和初步疗效。

要点

  • 极早产儿(<32周)营养需求高,母乳成分常不足以确保最佳生长,常需使用牛乳强化剂。
  • 牛乳强化剂可能增加喂养不耐受、坏死性小肠结肠炎和晚发型脓毒症风险。
  • 本先导试验将评估牛初乳强化剂的可行性、安全性和初步疗效。

核心结论

  • 该试验将记录牛初乳作为极早产儿母乳新型强化剂的可行性、安全性和初步疗效。

研究设计与样本

  • 开放标签多中心随机对照先导试验,计划纳入200名胎龄26+0至30+6周的极早产儿。
  • 随机分配至牛初乳强化剂组或牛乳强化剂组,添加至母乳和/或捐赠人乳中。

主要发现

  • 主要结局包括生长速率、坏死性小肠结肠炎和晚发型脓毒症发生率、一系列副临床终点及新型强化剂的实际可行性。
  • 将从临床数据以及血液和粪便样本中评估婴儿生长、代谢、肠道功能和免疫力的数据。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验注册为回顾性注册,于2018年5月25日在ClinicalTrials.gov注册,编号NCT03537365。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Very preterm infants (< 32 weeks gestation) have a relatively high nutrient requirement for growth and development. The composition of human milk is often inadequate to ensure optimal growth so it is common to fortify human milk for very preterm infants with nutrient fortifiers based on bovine milk. However, there are concerns that bovine milk-based fortifiers may increase the risk of feeding intolerance, necrotizing enterocolitis and late-onset sepsis. We hypothesize that a bovine colostrum-based product is a suitable alternative to bovine milk-based products when used as a fortifier to human milk in very preterm infants. METHODS/DESIGN: In an open-label multicentre randomised controlled pilot trial, 200 very preterm infants (26 + 0 to 30 + 6 weeks gestation at birth) will be randomly allocated to a bovine colostrum-based or a bovine milk-based fortifier added to mother's own milk and/or human donor milk. Outcomes are growth rate, incidence of necrotizing enterocolitis and late-onset sepsis, a series of paraclinical endpoints, and practical feasibility of using the novel fortifier for very preterm infants. DISCUSSION: The optimal enteral diet and feeding regimen for very preterm infants remain debated; this clinical trial will document the feasibility, safety and preliminary efficacy of using bovine colostrum, rich in nutrients and bioactive factors, as a novel fortifier for human milk to very preterm infants. Data on infant growth, metabolism, gut function and immunity will be assessed from clinical data as well as blood and stool samples. TRIAL REGISTRATION: Registered retrospectively 25 May 2018 at ClinicalTrials.gov: NCT03537365 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ahnfeldt AM, Hyldig N, Li Y, et al. FortiColos - a multicentre study using bovine colostrum as a fortifier to human milk in very preterm infants: study protocol for a randomised controlled pilot trial. Trials. 2019. PMID: 31118098. doi:10.1186/s13063-019-3367-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。